Atossa Q1 cash $65.1M; pivots (Z)-endoxifen to metastatic breast cancer

ATOSSA THERAPEUTICS, INC.

Ended Q1 2025 with $65.1M cash, no debt; no revenue reported.
Strategic shift to metastatic breast cancer as lead indication for (Z)-endoxifen.
Added 3 new US patents, expanding IP portfolio to over 200 claims related to (Z)-endoxifen.
Operating expenses $7.4M (up $0.4M YoY) with R&D $4.2M, G&A $3.3M.
Interest income $0.7M, down from $1.1M due to lower money market balance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.